ERNA Eterna Therapeutics
- 2.030
- -0.090-4.25%
Eterna Therapeutics News
10-Q: Quarterly report
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) IMSC Line With Enhanced Immunosuppressive Activity and Stealthing Features That May Further Augment the Therapeutic Potential of...
The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs
Press Release: Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to Its Scientific Advisory Board
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" o
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to Its Scientific Advisory Board
Eterna Therapeutics To Present at The ASGCT 27th Annual Meeting On Development Of Beta 2 Microglobulin-Knockout IMSC Line With Enhanced Immunosuppressive Activity And Stealthing Features
Eterna Therapeutics To Present at The ASGCT 27th Annual Meeting On Development Of Beta 2 Microglobulin-Knockout IMSC Line With Enhanced Immunosuppressive Activity And Stealthing Features
Factor Bioscience Expands Translational Science Team, Appoints Kyle Garland, Ph.D., as Director of Translational Science
CAMBRIDGE, Mass., April 9, 2024 /PRNewswire/ -- Factor Bioscience Inc. ("Factor"), a Cambridge, Massachusetts-based biotechnology company developing advanced mRNA and cell-engineering technologies, t
Earnings Week Ahead: Walgreens Boots Alliance, Carnival, GameStop and More
Eterna Therapeutics Inc On March 19, Received A Notice From Nasdaq Stating That Co Is Not In Compliance With Nasdaq Listing Rule 5550(B)(1)
Eterna Therapeutics Inc On March 19, Received A Notice From Nasdaq Stating That Co Is Not In Compliance With Nasdaq Listing Rule 5550(B)(1)
Press Release: Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to Its Board of Directors
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or t
Eterna Therapeutics Welcomes New Board Member Peter Cicala
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersRevance Therapeutics (NASDAQ:RVNC) shares moved upwards by 16.5% to $6.0 during Friday's pre-market session. The company's market cap stands at $526.8 million. Eterna Therapeutics (NASDAQ:ERNA)
Eterna Therapeutics Files to Sell 18.2M Shares for Holders
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (C)(4)
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide
Eterna Therapeutics Appoints Sanjeev Luther as President and CEO
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer
CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersAclarion (NASDAQ:ACON) shares rose 75.8% to $0.51 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.8 million. Longeveron (NASDAQ:LGVN) stock rose 43.
Eterna Therapeutics Launches Convertible Debt and Warrant Financing of up to $9.2M
Eterna Therapeutics Announces $9.2M Convertible Debt And Warrant Financing
Eterna Therapeutics Inc. a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the execution of
Press Release: Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Compan
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersC4 Therapeutics (NASDAQ:CCCC) stock increased by 100.5% to $2.37 during Tuesday's regular session. The market value of their outstanding shares is at $116.6 million. Aditxt (NASDAQ:ADTX) shares
Analysis
Price Target
No Data
